Get started
Technical Analysis of QCOMOverview of the Stock and Recent Price Action QCOM has experienced significant volatility over the past year, with notable movements that highlight key trading opportunities. From November 2023 to June 2024, QCOM enjoyed a strong uptrend, climbing from around $110 to a peak of approximately $220. However, after reaching this high, the stock entered a downtrend, declining to around $160 by November 2024. Step-by-Step Analysis 1. Trendlines and Channels Ascending Channel: Initially, QCOM was trading in a steep ascending channel, indicating a strong bullish trend until mid-2024. The subsequent downtrend has formed a descending channel, reflecting bearish market sentiment. 2. Fibonacci Retracement Levels Support: The $160 level has acted as a significant support area recently, with the stock bouncing off this level multiple times. Resistance: The $170 level is a notable resistance point. QCOM has struggled to break above this level in recent months. 3. Volume Analysis There are spikes in volume during significant price movements, such as the peak in June 2024 and the decline thereafter. This suggests strong investor interest and potential institutional activity during these periods. 4. Indicators and Events Earnings Announcements: Key earnings dates are marked on the chart, which can significantly impact price movements. Traders should watch for upcoming earnings reports. Potential Price Movement Bullish Scenario Entry Point: A break above the $170 resistance level with strong volume could signal a potential reversal and continuation of the uptrend. Stop Loss: Below $160 to limit downside risk. Profit Target: The next target would be in the $180-$190 range. Bearish Scenario Entry Point: A failure to hold the $160 support level could lead to further declines. Stop Loss: Above recent highs to avoid false breakdowns. Profit Target: The next support level would be around $150. Conclusion QCOM is currently in a consolidation phase between $160 and $170. A breakout above or below these levels, accompanied by strong volume, will likely determine the next significant price movement. Traders should monitor these key levels and be aware of upcoming earnings and dividend announcements.
NASDAQ:QCOM
by stocktechbot
WILL CARNIVAL CRUISE LINE ($CCL) CONTINUE TO SAIL HIGHER?! 50%+🚢 WILL CARNIVAL CRUISE LINE ( NYSE:CCL ) CONTINUE TO SAIL HIGHER?! 50%+ Potential! 🚢 NYSE:CCL had a rough ride during the COVID pandemic as everyone stayed home, not vacationing, and definitely not cruising. But could it be ready for a massive comeback? In my latest video, I break down the "High Five Setup" trading strategy, the ascending triangle breakout, and when to possibly enter this exciting trade. Trade Idea: Entry: $20 Exit: $17.88 PT1: $26 PT2: $30.64 Thanks for watching and for all the support! Let me know what stock or video you want to see next. LIKE | FOLLOW | SHARE Not financial advice. #StockMarket #Trading #Investing #CarnivalCruise #HighFiveSetup
NYSE:CCLLong
by RonnieV29
6
Celsius Holdings, Inc. (CELH) - Comprehensive Stock 1. Company Overview & Industry Outlook Celsius Holdings, Inc., a leader in the functional beverage industry, focuses on producing and distributing energy drinks and health-oriented beverages that cater to fitness-conscious consumers. The company's growth is driven by the increasing demand for healthier lifestyle options, as consumers shift from traditional sugary drinks to functional and energy-boosting alternatives. This market trend, supported by heightened awareness of health and wellness, provides a strong tailwind for Celsius in the energy drinks sector, which is expected to see continued expansion globally. 2. Financial Performance & Earnings Outlook Latest Earnings (Q2 2024): EPS: $0.29 Return on Equity (ROE): 70.73% Gross Profit Margin: 52.02% Quick Ratio: 3.73 Current Ratio: 4.43 Return on Investment (ROI): 19.58% Net Profit Margin: 19.85% Celsius has demonstrated impressive profitability metrics, with a high ROE and ROI that reflect efficient capital use and strong operational performance. The gross profit margin of over 50% highlights robust pricing power and cost management. Earnings Forecast: 2024 FY: Forecasted EPS at $0.78, gross income of $1.40B, and EBIT of $258.35M. 2025 FY: Forecasted EPS at $0.98, gross income of $1.63B, and EBIT of $329.86M. 2026 FY: Forecasted EPS at $1.23, gross income of $1.89B, and EBIT of $427.32M. The forecast shows steady growth in both revenue and earnings, indicating confidence in the company's ongoing expansion. Projected EPS growth is indicative of improved profitability, supporting the notion of a positive earnings trajectory in the coming years. 3. Stock Trend Analysis & Capital Flow Recent Price: $31.48 (as of Nov 3, 2024) Support Level: $31.40 Resistance Level: $33.60 Average Cost: $34.85 Capital Flow (Recent Days): Inflow: Significant, with $68.74M in inflow and $57.82M in outflow on the latest day, suggesting a net positive capital movement. 5-Day Summary: Mixed with days of strong inflows (e.g., 10-30 at $4.03M) and outflows (e.g., 10-29 at -$7.81M). The support and resistance levels indicate the price range where the stock might find buying and selling pressures, respectively. The overall inflow is relatively strong, suggesting some bullish sentiment, though recent volatility in capital flow indicates fluctuating investor confidence. 4. Analyst Ratings & Target Price Target Price: Average target of $44.87, with a low of $26 and a high of $68. Analyst Recommendations: 15 analysts cover CELH, with 5 “Strong Buy,” 9 “Buy,” 4 “Hold,” and 1 “Underperform” ratings. Analysts have a generally optimistic outlook on Celsius, with the average target price of $44.87 indicating a potential upside from the current levels. The range in price targets reflects different growth assumptions and market conditions, but the high number of “Buy” and “Strong Buy” ratings highlights positive sentiment. 5. Recent News & Sentiment Analysis Bullish News: The company's continuous innovation in product offerings and expansion into new markets has garnered positive attention, with Celsius capitalizing on growing demand for energy drinks that align with health trends. Bearish News: Rising competition in the energy and functional beverage market could challenge Celsius’s growth pace. Furthermore, any increase in production costs or supply chain disruptions might impact profit margins. The balance of news appears slightly bullish due to strong brand positioning and market expansion, though competitive pressures and operational challenges remain factors to monitor. Conclusion & Outlook Celsius Holdings is well-positioned to benefit from industry growth in the health-oriented beverage market. With a strong financial foundation, favorable earnings outlook, and positive analyst sentiment, the stock presents a solid case for growth. However, potential investors should consider market volatility, competitive risks, and industry dynamics. Disclaimer: This analysis is not investment advice. Please consult with a financial advisor and conduct your own research before making any investment decisions.
NASDAQ:CELHLong
by Joekenstein7
Relay Therapeutics (RLAY) Stock AnalysisCompany Overview Relay Therapeutics, a biotech firm focused on drug discovery through precision oncology, operates in the high-growth field of pharmaceutical R&D, particularly targeting oncology therapies. The biotechnology industry, with a focus on cancer and rare diseases, is anticipated to grow robustly due to increasing innovation and demand for effective treatments. Relay's unique platform leverages computational technology to discover and design new drugs faster, potentially setting it apart in a competitive market. Recent Earnings and Forecast Q2 2024 Earnings: Relay reported an EPS of -$0.69, reflecting the high R&D expenses typical in biotech firms. Their Return on Equity (ROE) was -51.68%, indicative of ongoing investment in research rather than profitability. The company maintains strong liquidity with a quick ratio of 15.28 and a current ratio of 15.64, suggesting ample short-term financial stability. Future Forecasts: 2024: Expected EPS of -$2.84 with a forecasted EBIT loss of $416.16 million. 2025: Projected EPS of -$3.14, with a slight increase in revenue anticipated, reflecting the slow commercialization phase of biotech firms. 2026: Although expected EPS remains negative at -$3.12, revenue is forecasted to reach $16.47 million, marking early signs of operational progress. These figures highlight that while Relay Therapeutics remains in a high-burn phase, future revenue growth may signal eventual returns on its research investments. Recent Stock Trends Current Price: $5.84 as of November 3, 2024. Capital Flow: Over the past five days, capital flow has been mixed, with net outflows on certain days (e.g., October 25 and October 31), but occasional inflows as well, suggesting fluctuating investor interest. One-Day Flow: Total inflow of $2.0678 million, with an outflow of $2.5102 million, showing slight net selling pressure. Technical Indicators: Support Price: $5.78 Resistance Price: $7.84 Average Cost for Investors: $8.68, indicating potential upside if the price recovers above this average. This mixed capital flow data and the significant gap between the support and resistance levels indicate ongoing volatility with potential short-term fluctuations. Analyst Viewpoints Price Target: Analyst target price averages at $22.30, with a range of $16.00 to $30.00, suggesting strong long-term potential if the company achieves milestones in its drug pipeline. Recommendations: Of 10 analysts, 6 suggest buying the stock, 1 recommends holding, and 3 suggest a strong buy. These targets indicate optimism from analysts who likely foresee breakthrough potential in Relay's clinical trials and product development. Market News and Sentiment The stock's recent movements are partially influenced by the overall biotech market, which has seen increased volatility amid earnings season. Broader market conditions, including shifts in investor sentiment and economic uncertainty, are also contributing factors. No specific company-related news was identified, but capital outflows suggest cautious sentiment among investors, potentially waiting for clear clinical progress before making larger commitments. Investment Summary Bullish Factors: Relay's innovative approach in precision medicine and the high analyst target price signify its potential as a high-reward investment, especially if upcoming trials deliver favorable outcomes. Bearish Risks: The company is in a high cash-burn phase with ongoing losses. Significant downside could occur if clinical milestones are delayed or fail. Disclaimer The above analysis is for informational purposes only and should not be considered investment advice. The stock market carries inherent risks, and investors should conduct their own research or consult with a financial advisor before making investment decisions.
NASDAQ:RLAYLong
by Joekenstein7
Ford Motor Company (NYSE: F) - November 2024 StockOverview Ford Motor Company, headquartered in Dearborn, Michigan, is a global automotive and mobility company known for its Ford+ plan, which focuses on combining its strengths in traditional vehicles with new capabilities in electric vehicles (EVs) and digital customer experiences. Ford operates through three main segments: Ford Blue: Developing iconic gas-powered and hybrid vehicles. Ford Model e: Focusing on innovative EVs and embedded software for enhanced digital experiences. Ford Pro: Serving commercial customers with vehicles and services tailored to their needs. Ford employs approximately 175,000 people worldwide and also offers financial services through Ford Motor Credit Company. Recent Developments Stock Performance: Ford's stock recently traded at $10.22, shedding 0.68% in a recent session, underperforming some of its competitors, such as Tesla. Trading volume was lower than the 50-day average, suggesting reduced investor activity or interest at this price level. Dividend Update: Ford announced a $0.15 dividend per share to be paid on December 2, offering a 7.6% yield, which is considered attractive for income-focused investors. The projected earnings growth and a conservative payout ratio of around 37% suggest the sustainability of this dividend. Q3 2024 Financial Results: Ford reported $46.196 billion in revenue, marking an increase from the previous year's $43.801 billion. Net income, however, declined to $892 million from $1.199 billion in the same quarter last year, highlighting some profitability challenges. Key elements of the Ford+ strategy were discussed during the Q3 earnings call, emphasizing a focus on growth in EV and connected vehicle services. Strategic Initiatives: Ford+ Plan: Continues to drive the company's transformation towards sustainable growth and value creation through innovation in EVs, cost improvements, and expansion in the Ford Pro segment. Cost Optimization: Ford is actively working on cost improvements and restructuring efforts to boost profitability. Manager Incentives: Ford is linking manager bonuses to performance metrics, reflecting a push for accountability and strategic alignment within the company. SWOT Analysis Highlights: Strengths: Strong legacy in automotive manufacturing, established brand value, and a growing EV presence. Weaknesses: Declining profitability, competition from EV-focused companies like Tesla. Opportunities: Expansion in EV offerings, digital transformation, and cost improvements. Threats: Intense competition in the EV market, potential macroeconomic challenges affecting demand. Outlook Ford’s future outlook appears to be a mix of cautious optimism and strategic challenges: Bullish Factors: A sustainable dividend policy, offering a high yield. The Ford+ plan positions the company for growth in the EV and digital service market segments. Revenue growth in recent quarters indicates potential resilience in core business areas. Bearish Factors: Declining net income in recent quarters points to profitability challenges. Underperformance compared to peers in the stock market raises concerns about investor sentiment. High competition in the EV market may pressure Ford's ability to capture significant market share. Conclusion On balance, Ford Motor Company presents a stable dividend-paying stock with strategic initiatives aimed at long-term transformation through its Ford+ strategy. While profitability issues and competition in the EV space are notable risks, Ford’s efforts in cost management and EV expansion offer some upside potential.
NYSE:FShort
by Joekenstein7
Faraday Future Inc. Stock Analysis1. Company Overview Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) is an electric vehicle (EV) company that has faced significant challenges in bringing its products to market. The company focuses on developing luxury EVs and has plans to introduce artificial intelligence-enhanced electric vehicles (AIEVs) under its second brand, Faraday X. Despite a limited number of vehicle deliveries, Faraday Future has managed to attract some investor attention and has been involved in efforts to raise capital and expand operations. 2. Recent News Highlights October 31, 2024: Faraday Future filed with the SEC to sell 29.66 million shares of its Class A common stock, reflecting the company’s need to raise funds to support operations and product development. October 25, 2024: Faraday signed agreements for development projects in Ras Al Khaimah, which include office and engineering space and an operational hub. Construction is expected to begin by the end of 2024, with occupancy anticipated in late 2025. September 2024: Faraday announced the launch of Faraday X, its second brand focused on AI-enhanced EVs, indicating a shift toward integrating advanced AI technology into its EV offerings. 3. Stock Price Performance Current Price: As of the latest data, Faraday Future's stock has been fluctuating, influenced by a mix of capital raising announcements, operational updates, and general market sentiment. Technical Trends: Faraday's stock exhibits volatility, typical for companies in the early growth phase with high investor expectations but limited product delivery. The stock saw a boost with the announcement of its Faraday X brand, which suggests interest in its technological innovation prospects. 4. Financial Challenges and Capital Raising Faraday has faced ongoing financial constraints, which it has sought to address through issuing new shares. The company’s low cash reserves and limited revenue from vehicle sales necessitate these capital-raising activities, though they also create dilution risks for existing shareholders. 5. Future Outlook and Potential Growth Opportunities: Faraday Future has plans to expand its footprint internationally, including its Ras Al Khaimah developments. This expansion could increase operational capacity and strengthen its supply chain for the Faraday X brand. AI and Innovation: The company’s focus on AI-driven vehicles with Faraday X is positioned as a differentiator in the competitive EV market. However, the success of this endeavor depends on successful execution and securing the required capital. Risks: Despite potential, Faraday faces significant risks, including cash flow issues, production challenges, and competitive pressure from established EV players. Market analysts remain cautious due to these factors, and the stock is considered speculative. 6. Target Price and Investment Outlook Price Prediction: Based on the company's high volatility, uncertain financial health, and speculative position in the market, price predictions remain highly variable. Near-term movements are likely tied to announcements related to funding, partnerships, or production milestones. Investment Recommendation: Investors should consider Faraday Future a high-risk, high-reward speculative stock. The bullish factors include innovative AI-based vehicle concepts and expansion plans, while the bearish factors focus on cash flow challenges and limited product delivery. Caution is advised for investors, as the stock remains speculative and heavily dependent on future capital infusions. 7. Conclusion Faraday Future Inc. represents a potential high-reward opportunity in the EV market, with an emphasis on AI-driven technology. However, its financial challenges and operational hurdles create significant investment risks. This stock may be of interest to risk-tolerant investors who are willing to wait for potential future breakthroughs in Faraday's technology and market positioning.
NASDAQ:FFIEShort
by Joekenstein7
IS THIS MAG7 DARLING ABOUT TO CRASH?!NASDAQ:MSFT 🔥 IS NASDAQ:MSFT ABOUT TO FALL OVER 21%?! 🔥 Let's not panic yet, but Microsoft's weekly charts are flashing some intriguing signals. Here’s the lowdown: As long as NASDAQ:MSFT stays within its symmetrical pattern, we’re in the clear. But if it breaks downward, we’re looking at a potential 6% drop from the Volume profile shelf and possibly a dangerous 22% plunge, breaking the 2024 Head & Shoulders pattern. Enter the "Low Five Setup"—the bearish counterpart to my "High Five Setup." Key factors to watch: - Williams %R: Lower High - MACD: Dangerously close to crossing below the zero line (BEARISH) - RSI: Below RSI MA with lower highs, at 46—lots of room before oversold - Trend: Lower high, red through yellow downward move indicating a downtrend on the weekly chart Microsoft has been Wall Street’s golden goose, untouched by the FUD that hit the MAG7 stocks. Apple had China FUD, Tesla faced the ELON BAD FUD, Google with AI SEARCH FUD, Amazon with spending and margins FUD, Meta with metaverse spending FUD, and Nvidia with growth concerns FUD. But as Willy Wonka taught us, every golden goose lays a bad egg sometimes. This is a weekly chart setup, so it will take time to play out. No one's immune to Wall Street’s FUD wrath, not even Microsoft. We shall see what happens... P.S. I’m not in this name yet—just putting it on your radar. We’re early to the party, just like I always am with my setups. If you’re still here, you value solid, well-thought-out market analysis. Props to you! Have a great Sunday, friends! 👊 Not Financial Advice #HighFiveSetup #LowFiveSetup
NASDAQ:MSFT
by RonnieV29
CareMax Inc. Stock Analysis1. Company Overview CareMax Inc. is currently focused on measures to stabilize its financial situation. In October 2024, the company announced that it is undergoing efforts to reduce operating expenses and pursue refinancing options in both equity and debt markets. In case these efforts do not yield sufficient results, CareMax may consider restructuring under Chapter 11 bankruptcy. Additionally, the company is exploring strategic alternatives, which could include the sale of certain assets. The recent announcements have introduced substantial doubt about CareMax’s ability to continue as a going concern. Key Articles: CareMax to Pursue Strategic Alternatives, Including Sale of Certain Assets Efforts to Reduce Operating Expenses and Pursue Various Equity and Debt Refinancing 2. Recent Earnings Overview (2024 Q3) The earnings data for Q3 2024 has not provided specific metrics. However, an analysis of the earnings report would typically compare the reported metrics to market expectations and previous year’s results to determine performance trends. 3. Volatility in October 2024 Throughout October 2024, CareMax's stock experienced heightened volatility. This was likely driven by investor concerns regarding the company’s financial stability, following announcements about the possibility of restructuring under Chapter 11 if refinancing and cost-cutting efforts are insufficient. This news has cast doubt on the company's future, impacting investor confidence and contributing to significant stock fluctuations. 4. Future Price Prediction There is currently no specific target price forecast available for CareMax Inc. Further analysis would depend on updates regarding the company’s refinancing progress and strategic alternative pursuits. 5. Outlook Summary Bullish Factors: If CareMax successfully secures refinancing and implements effective cost reductions, it could stabilize its financial position. Strategic asset sales might generate needed liquidity, supporting the company’s continued operations. Bearish Factors: The potential for Chapter 11 restructuring poses a serious risk, signaling financial distress and uncertainty for shareholders. The ongoing concern about the company's viability could lead to prolonged volatility or downward pressure on the stock price. Conclusion: CareMax Inc. faces a challenging outlook. The balance of risks currently leans toward a bearish view due to the uncertainty around restructuring and financing efforts. Investors should closely monitor news regarding these financial maneuvers to gauge the stock’s potential future direction.
NASDAQ:CMAXShort
by Joekenstein7
My last resort for a bull caseI admit the earnings reaction was a bit of a surprise to me, but I'm only writing this because I was in denial of the technical signs I clearly saw. The Oct 9 - Oct 23 leg down was in five waves, so I should've anticipated that upon the earnings, we will move down - the move up in the days prior to the earnings was in three and retraced to the 61.8 - 78.6% zone. Right now, I am leaning towards a $100 price target, I give it about 90% chance. However, I am giving it a tiny chance that the set of threes which have been printing since the March 8 ATH is forming an ABCDE triangle. If so, the local low is in and we move higher from here.
NASDAQ:AMD
by BelaK
Olaplex Holdings Inc. (NASDAQ: OLPX) - Overview and InvestmentCompany Overview Name: Olaplex Holdings Inc. Ticker: OLPX (NASDAQ) Industry: Haircare Founded: 2014 Products: Scientifically formulated haircare treatments for repairing and strengthening hair against chemical, thermal, and mechanical damage. Olaplex Holdings Inc. is a well-regarded company in the haircare industry, known for its patented products designed to repair damaged hair. Its products are used both in professional salon settings and by consumers globally. Olaplex’s innovative formulas have made it a preferred choice for haircare professionals and customers seeking reliable repair solutions. Recent Developments Upcoming Financial Results Olaplex will report its third-quarter fiscal 2024 financial results on November 7, 2024. This announcement is anticipated to provide deeper insights into Olaplex’s revenue, profitability, and future guidance. Investors will closely watch this report to assess the company’s financial health and growth trajectory. Source: Olaplex to Report Q3 Financial Results on November 7 Analyst Rating Recently, Telsey Advisory’s analyst Dana Telsey maintained a Hold rating on Olaplex with a price target of $3.00. This rating reflects a neutral outlook, suggesting that Olaplex’s current price is in line with the analyst’s valuation and growth expectations. Source: Telsey Advisory Reiterates Hold on Olaplex Interest from Michael Burry’s Hedge Fund Scion Asset Management, the hedge fund managed by prominent investor Michael Burry, has included Olaplex in its top 10 stock picks for 2025. This attention from a high-profile investor indicates that Olaplex may be seen as undervalued or positioned for potential growth, highlighting Burry’s confidence in the company’s business model or future potential. Source: Olaplex Among Michael Burry’s Top 10 Picks Stock Price Performance and Recent Chart Analysis The latest trading charts show that Olaplex Holdings Inc. has seen a significant fluctuation in its stock price, which is closely aligned with broader market movements and sector trends. Analysts and investors may look to recent volume and price action for insights into market sentiment. The upcoming earnings report could be a key catalyst affecting short-term stock movement. Future Price Prediction and Target Price According to recent analyses and expert projections, Olaplex’s current target price is set at approximately $3.00 by Telsey Advisory. This target reflects a conservative outlook, in line with the company's recent performance and potential challenges in maintaining rapid growth within the competitive haircare sector. Investment Outlook Bullish Indicators Strategic Position in Haircare Market: Olaplex’s reputation for innovative and effective hair repair solutions gives it an edge within a niche yet growing sector. Institutional Interest: Interest from a high-profile hedge fund, such as Michael Burry's Scion Asset Management, suggests that Olaplex may be viewed as an undervalued opportunity with the potential for future appreciation. Bearish Indicators Neutral Analyst Sentiment: With a Hold rating and a modest target price of $3.00, analysts appear cautious regarding Olaplex's near-term potential, perhaps due to market competition or slowing growth. Upcoming Financial Results Uncertainty: The impending financial results announcement could either validate the company's current valuation or lead to increased volatility if performance fails to meet expectations. Overall Assessment On balance, while Olaplex benefits from brand strength and institutional interest, its immediate outlook appears moderate, with analysts expressing caution. The potential for growth may largely hinge on the November 7 earnings report and subsequent market reaction. Conclusion Based on the information gathered, Olaplex Holdings Inc. presents a mixed investment outlook. While the company is a leader in a unique market segment and has gained attention from prominent investors, analysts currently recommend a hold position. Investors may want to keep an eye on the upcoming earnings release, as it could provide key insights into Olaplex's financial health and growth strategy.
NASDAQ:OLPX
by Joekenstein7
Datasea Inc. (NASDAQ: DTSS) Stock AnalysisCompany Overview: Datasea Inc. operates within the technology sector, specializing in cybersecurity, smart city technology, and digital solutions that leverage big data and artificial intelligence. The industry holds significant potential, driven by growing global demand for advanced security and digital solutions, especially as cities and businesses increasingly adopt smart technologies. As smart city infrastructure expands and data security becomes a higher priority, Datasea's market is poised for potential growth. However, the company also faces strong competition from established technology giants and other players in cybersecurity. Latest Earnings and Forecast: While there are no recent detailed earnings figures available, Datasea is expected to benefit from increasing interest in digital and cybersecurity solutions. Forecasts suggest steady but modest growth as the company seeks to capitalize on emerging market opportunities. Investors are keenly watching for future earnings reports to see if Datasea can convert its technological advancements into financial gains. Recent Stock Trends and Capital Flow: Capital Flow (5-Day Trend): 10-25: Inflow of 11,651 Yuan. 10-28: No significant activity. 10-29: Outflow of 11,843 Yuan. 10-30: Inflow of 8,225 Yuan. 10-31: Inflow of 9,072 Yuan. 1-Day Summary: Inflow of 64,200 Yuan versus an outflow of 71,600 Yuan. The significant outflows in the recent sessions indicate potential profit-taking or caution among investors after recent gains. Support and Resistance Levels: Support Price: $2.01 (as of 2024-11-01) Resistance Price: $3.01 (as of 2024-11-01) Average Cost: $2.97 Current price sits around $2.42 (as of 2024-11-03), meaning it’s between support and resistance levels. If the stock breaks the resistance at $3.01, it could see further gains. However, falling below $2.01 would be a bearish signal. Analyst Insights: Target Price: One analyst has set a target price of $1.50, which indicates potential downside from the current price level of $2.42. Recommendation: The sole analyst covering DTSS has given a "buy" rating, suggesting cautious optimism but with a limited upside based on current target estimates. Recent News and Sentiment: There have been no specific recent news releases for Datasea Inc. that drastically affect the stock price. However, investor sentiment could be influenced by broader market factors affecting tech and cybersecurity stocks, such as cybersecurity threats, new government regulations, or large-scale cyberattacks that emphasize the need for improved digital infrastructure. Bullish Indicators: Growth in the cybersecurity and smart city sectors. Rising demand for digital transformation and advanced security in urban and corporate environments. Bearish Indicators: Modest target price from analysts relative to current levels. Capital outflow in recent sessions, possibly indicating investor caution. Outlook and Conclusion: Datasea Inc. shows potential within its niche in the digital and cybersecurity space, especially as urban centers increasingly adopt technology for smart infrastructure. The stock appears to have support around $2.01 and resistance at $3.01, with a cautious analyst outlook at a $1.50 target. Investors may view the stock as a speculative opportunity within the cybersecurity industry, but the limited analyst coverage and recent capital outflows suggest caution. Disclaimer: The above analysis is not investment advice. Stock prices fluctuate and investing in equities carries risks. It is recommended to conduct further independent research or consult a financial advisor before making any investment decisions.
NASDAQ:DTSSLong
by Joekenstein7
DJT - Parabolic Move IncomingPolitics aside, NASDAQ:DJT is about to begin the most insane of rallies. This chart for me is as clean as they come! Recent Price Action The last 2 days of October saw a ~45% correction, completing an Elliott Wave 2 correction. This after a bullish initial Wave 1 formation saw it go beyond even the most bullish of bullish initial price targets, in just 2 weeks flat. Price had prior to that been compressed inside a downwards-pointing wedge pattern (orange lines), since late March 2024. Over-shooting below it even, which is one of my most favourite bullish chart patterns. After breaking out of that, it is now not-only putting the finishing touches to an Inverse Head & Shoulder pattern (grey lines)... but when it does so it will also complete a massive Cup & Handle formation (white arrows). Future Price Targets The initial target (T1) from this move would be $570 (18x) in a very short period, perhaps even just 2 months. This would coincide with the 1.414 fibonacci level from the previous introduction of this stock (formerly DWAC) to public markets. Thereafter, an extended 5th wave target of $1,030 (33x) could be reached somewhere between early February and late May 2025. This coincides with the 1.618 fibonacci level (darker blue T2 line). Price as of today has back-tested the red horizontal line, in very quick fashion. This is the 0.382 fibonacci level. Next Up... Price may well end-up sideways on Monday and going into Tuesday's pivotal election day - which may allow the RSI to come back a little more to the mid 40s on this timeframe, to retest the RSI bull zone for support. From there I expect late Tuesday early Wednesday NASDAQ:DJT will have had a sufficient amount of time to cool-off - such that we can call the completion of a Wave 2 correction. Before the hugely exciting 3rd & 5th waves await us. Possible Elliott Waves Wave 1 - $12 to $55 Wave 2 - $55 to $30 Wave 3 - $30 to $570 Wave 4 - $570 to $140 Wave 5 - $140 to $1,030 Sounds ridiculous, right? Short squeeze, or election euphoria - call it what you want. But if you thought you'd seen NASDAQ:DJT volatility in recent days, think again. This is an incredible opportunity - with many many patterns aligning. NASDAQ:DJT has a lot of room to the upside still from here. Not sure this stock can any longer be suppressed.
NASDAQ:DJTLong
by DigiDavid
18
Palantir will move after earnings so hold tight ! As long as Palantir remains within the upward channel, it’s still in play! There’s an imbalance guiding the price, preventing it from dropping. We’ve seen the price attempt to go up twice already, so as long as Palantir stays within the channel and respects the imbalance, I’m quite confident it will make a third attempt to break the high. On the other hand... We have the earnings report coming up Monday pre-market, so whatever happens at the open, we’ll know which direction the price will take based on the report’s results. Keep a close eye on this! Best regards.
NYSE:PLTR
by RocketMike111
Nvidia So close to earnings report ! here is my analysis... In this chart, I haven't moved anything at all since my previous analysis of Nvidia. The price is making its natural movement just as we’ve been predicting. As you can see, the last candle closed by bouncing off my order block and following the pattern of my forecast arrow.(yellow dotted arrow) Based on the price behavior, we can predict that as it gets closer to November 20 — the earnings report date — it will simply be accumulating. Nvidia's last earnings reports have been phenomenal, and I don’t doubt that this report will be a trigger for the price to make a decision. But for now, we’ll only see the price in a range until a few days before the report, when we’ll see those high-volume candles that will drive the price in a single direction. Which direction? The one the report indicates. Best regards!
NASDAQ:NVDA
by RocketMike111
RIOT: moving stop loss upRIOT is at a spot where only a 3 waves sequence has completed. If abc move is the end of this sequence, then there is no reason for holding on at the moment. But in case a wave 5 is due, we might still be in for some good size gains. So, instead of completely getting out, I have taken profit at wave 3 and now have moved the stop loss up right below Thursday low. The whole thing can be part of a larger ABC pattern or if we have a full 5 waves up, then it might be start of a much larger wave 3 sequence. So, I will try to keep some skin in the game. Leave a bit that I can afford to lose completely and not lose any sleep over it...
NASDAQ:RIOT
by mukit1
4
MIRA - Ketamine Biotech Company with massive growth potential!Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. Float 9.96M Recent News from 29/10/2024: MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain "MIRA Pharmaceuticals (MIRA, Financial) shares soared by 40% after the company achieved a significant breakthrough in chemotherapy pain management with its new drug, Ketamir-2. According to recent studies, Ketamir-2 is proven to be 2% more effective than existing FDA-approved medications, specifically Gabapentin and Pregabalin, in alleviating chemotherapy-induced neuropathic pain. Preclinical studies have highlighted Ketamir-2's superior performance, demonstrating a 60% higher efficacy compared to Gabapentin and a remarkable 112% improvement over Pregabalin in various neuropathic models. Chronic neuropathic pain, in particular, which develops from nerve damage caused by chemotherapy or injury, has only Gabapentin and Pregabalin available as effective therapy now. Alas, such medications are not without their drawbacks, which include dizziness, impairment of cognitive function, and dependency inclusion. The market for both Gabapentin and Pregabalin is going to have healthy growth rates in the forecast period of 2020 to 2033, with Gabapentin reaching $4.95 Billion. Ketamir-2's superior performance in preclinical studies is coupled with fewer adverse side effects, presenting a potentially safer option for long-term pain management. This non-opioid alternative addresses the urgent need for treatments that minimize the risk of addiction. With its promising results, Ketamir-2 may soon qualify for FDA breakthrough therapy designation or fast-track status, especially for rare cancer-related neuropathic pains. In addition to ketamine-2, MIRA Pharmaceuticals is also active in developing MIRA-55, an oral agent with a similar mechanism as ketamine-2 used in the treatment of anxiety and cognitive symptoms in early dementia. With Ketamir-2 moving towards clinical trial and possibly receiving expedited approval by the FDA, it becomes a true light at the end of the tunnel for those suffering from chronic and severe pain." Overall Market Sentiment: It’s always crucial to consider overall market sentiment when making trading decisions. Breakout Zone: $2.60 - 2.65 Resistance Points: $3.30 $3.75 $4.15 $5.15 Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains. Trading Strategy: I see a cup and handle formation. Take Profit (TP): Set a target at $6.33. If FDA approval is granted, this stock has the potential to surge significantly, with a possible price target of $15.00 or even higher. Stop Loss (SL): Set at under $1.3 to mitigate potential losses. Chart Analysis: Please refer to the attached chart for detailed analysis of price trends and movements. Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities. Disclaimer: This content is for informational purposes only and should not be considered financial advice.
NASDAQ:MIRALong
by meitshels_smell_trades
Little rally to trap everyone? Then were caught holding the bag?10-11 expiration for NVDA has way to much open interest at 120 - 130 levels. 118 looks more realistic. I think we can see a climb to 120-130 early in the week and a huge sell off to 118 to end the week. If this happens, it opens the door to max pain of 112 - 113 by 10/18. There are going to be so many traps this months and I think were all in the middle of one now. Inversely, my theory above could be a trap as well haha. If this is truly a blow off top, $149 -$150 is my absolute peak.
NASDAQ:NVDAShort
by LeapTrades
12